Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis

  • Villacieros-Álvarez, Javier
  • Espejo, Carmen|||0000-0001-9949-5901
  • Arrambide, Georgina|||0000-0002-2657-5510
  • Castillo Juárez, Mireia|||0000-0001-8979-3219
  • Carbonell-Mirabent, Pere|||0000-0003-1349-9261
  • Rodriguez, Marta
  • Bollo, Luca|||0000-0002-3673-2030
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Galan, Ingrid|||0000-0001-5774-4260
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Mongay-Ochoa, Neus|||0000-0002-0338-4797
  • Nos, Carlos|||0000-0002-3830-4910
  • Río, Jordi|||0000-0003-4546-7627
  • Rodríguez Acevedo, Breogán|||0000-0002-0314-753X
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Tur, Carmen|||0000-0003-1849-3184
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Vilaseca, Andreu|||0000-0001-8147-8505
  • Zabalza, Ana|||0000-0003-3860-5251
  • Auger, Cristina|||0000-0001-9846-4767
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
  • Cobo-Calvo, Álvaro|||0000-0002-2574-0721
Objective: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) distinguish multiple sclerosis (MS) from MOG-associated disease in most cases. However, studies analyzing MOG-Ab at the time of a first demyelinating event suggestive of MS in adults are lacking. We aimed to (1) evaluate the prevalence of MOG-Ab in a first demyelinating event suggestive of MS and (2) compare clinical and paraclinical features between seropositive (MOG-Ab+) and seronegative (MOG-Ab-) patients. Methods: Six hundred thirty adult patients with available serum samples obtained within 6 months from the first event were included. MOG-Ab were analyzed using a live cell-based assay. Statistical analyses included parametric and nonparametric tests, logistic regression, and survival models. Results: MOG-Ab were positive in 17 of 630 (2.7%). Fourteen out of 17 (82.4%) MOG-Ab+ patients presented with optic neuritis (ON) compared to 227of 613 (37.0%) MOG-Ab- patients (p = 0.009). Cerebrospinal fluid-restricted oligoclonal bands (CSF-OBs) were found in 2 of 16 (12.5%) MOG-Ab+ versus 371 of 601 (61.7%) MOG-Ab- subjects (p < 0.001). Baseline brain magnetic resonance imaging (MRI) was normal in 9 of 17 (52.9%) MOG-Ab+ versus 153 of 585 (26.2%) MOG-Ab- patients (p = 0.029). Absence of CSF-OBs and ON at onset were independently associated with MOG-Ab positivity (odds ratio [OR] = 9.03, 95% confidence interval [CI] = 2.04-53.6, p = 0.009; and OR = 4.17, 95% CI = 1.15-19.8, p = 0.042, respectively). Of MOG-Ab+ patients, 22.9% (95% CI = 0.0-42.7) compared to 67.6% (95% CI = 63.3-71.3) of MOG-Ab- patients fulfilled McDonald 2017 criteria at 5 years (log-rank p = 0.003). Interpretation: MOG-Ab are infrequent in adults with a first demyelinating event suggestive of MS. However, based on our results, we suggest to determine these antibodies in those patients with ON and absence of CSF-OBs, as long as the brain MRI is not suggestive of MS. ANN NEUROL 2024;95:116-128.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

  • Lunemann, Jan
  • Valls Carbó, Adrián
  • Fernández, Victoria
  • Villacieros-Álvarez, Javier
  • Sepulveda, Maria
  • Dinoto, Alessandro
  • Vilaseca Jolonch, Andreu
  • Castillo Juárez, Mireia
  • Espejo, Carmen
  • Cobo-Calvo, Alvaro
  • Tintore, Mar
  • Comabella Lopez, Manuel
  • Arrambide, Georgina
  • Montalban, Xavier
  • Bollo, Luca
Complement activation; Clinical outcomes; Myelin oligodendrocyte glycoprotein, Perfiles de activación; Resultados clínicos; Glucoproteína de oligodendrocito de mielina, Activació del complement; Resultats clínics; Glicoproteïna d'oligodendròcits de mielina, Background and Objectives The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis are lacking. We aimed to investigate the value of complement factors (CFs) as diagnostic and prognostic biomarkers in patients with MOGAD. Methods Multicentric retrospective cohort study including patients with MOGAD, multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD) with available paired serum and CSF samples. A panel of CFs were measured by multiplex ELISA, and the levels were compared between the 3 conditions. Univariable and multivariable analyses were performed to evaluate the association between levels of CFs and relapse and disability outcomes in MOGAD patients. Results Ninety-four patients (MOGAD, n = 60; MS, n = 18; AQP4-NMOSD, n = 16) were included. Mean (SD) age at sampling was 39.4 (16.7), 40.7 (7.0), and 43.3 (21.0), respectively. Female were predominant, especially in AQP4-NMOSD (88%). Combination of the serum levels of C3a, C4a, and C3a/C3 ratio showed excellent potential to discriminate MOGAD from patients with MS (area under the curve [AUC] [95% CI] 0.95 [0.90–0.99]) and from AQP4-NMOSD (AUC 0.88 [0.76–1.00]). In patients with MOGAD, CSF levels of CFs of the classical/lectin pathway influenced relapse-related outcomes, and lower C4 levels were associated with higher number of relapses during follow-up (incidence rate ratio [95% CI] 0.88 [0.78–0.99]; p = 0.04 in multivariable analysis), and a high C4a/C4 ratio was associated with increased risk of second relapse during the first year (hazard ratio [95% CI] 3.68 [1.26–10.78]; p = 0.02 in multivariable analysis). Time to second relapse was shorter in patients with MOGAD with a high CSF C4a/C4 ratio (log-rank p = 0.01). CSF levels of the membrane attack complex SC5b9 influenced disability-related outcomes, and baseline CSF SC5b9 levels were higher in patients who reached the final Expanded Disability Status Scale (EDSS) ≥ 3.0 (p = 0.002), and elevated SC5b9 levels were associated with increased risk of reaching EDSS ≥ 3.0 (odds ratio [95% CI] 1.79 [1.16–3.67]; p = 0.04 in multivariable analyses). Discussion Our results suggest that serum and CSF levels of CFs have diagnostic and prognostic value respectively in patients with MOGAD. These findings support the use of complement inhibitors as a therapeutic approach in these patients., The study was funded thanks to a legacy from Mrs. Adela Arbó. J.V.-A. received grant from Instituto de Salud Carlos III, Spain; FI21/00282.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease

  • Mulero, Patricia
  • Rubio-Flores, Laura
  • Villacieros-Álvarez, Javier
  • Espejo, Carmen
  • Dinoto, Alessandro
  • Rovira, Alex
  • Auger, Cristina
  • Tintore, Mar
  • Cobo-Calvo, Alvaro
  • Arrambide, Georgina
  • Montalban, Xavier
Serum Cytokines; Prognosis; Myelin oligodendrocyte glycoprotein, Citocinas séricas; Pronóstico; Glicoproteína de oligodendrocitos de mielina, Citocines sèriques; Pronòstic; Glicoproteïna d'oligodendròcits de mielina, Objectives To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (≤3 months from disease onset) and follow-up (≥6 months from the baseline), and age-matched and time to sampling–matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Results Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non–optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). Discussion This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions., This study has been funded by Instituto Carlos III through the projects PI20/00800 granted to A.C.-C. and Fondation pour l'aide à la recherche sur la sclérose en plaques (ARSEP) (ARSEP-1276). A. Cobo-Calvo is supported by Joan Rodes contract JR19/00007 and Javier Villacieros-Álvarez by P-FIS grant FI21/00282.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder

  • Carta, Sara
  • Dinoto, Alessandro
  • Capobianco, Marco
  • Valentino, Paola
  • Montarolo, Francesca
  • Sala, Arianna
  • Villacieros-Álvarez, Javier
  • Cobo-Calvo, Alvaro
  • Arrambide, Georgina
Serum biomarker; Neuromyelitis optica spectrum disorder, Biomarcadores séricos; Trastorno del espectro de neuromielitis óptica, Biomarcadors sèrics; Trastorn de l'espectre de neuromielitis òptica, Background and Objectives Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) serum levels are useful to define disease activity in different neurologic conditions. These biomarkers are increased in patients with aquaporin-4 antibody–positive NMOSD (AQP4+NMOSD) during clinical attacks suggesting a concomitant axonal and glial damage. However, there are contradictory results in double seronegative NMOSD (DS-NMOSD). The aim of this study was to characterize the neuronal, axonal, and glial damage of DS-NMOSD in comparison with AQP4+NMOSD. Methods Patients with DS-NMOSD (i.e., for AQP4 and myelin oligodendrocyte glycoprotein antibodies—MOG-Abs) and age-matched AQP4+NMOSD diagnosed according to the latest diagnostic criteria and with available serum samples obtained within 3 months from onset/relapse were retrospectively enrolled from 14 international centers. Clinical and radiologic data were collected. Serum NfL, GFAP, tau, and UCH-L1 levels were determined using an ultrasensitive paramagnetic bead–based ELISA (SIMOA). Statistical analysis was performed using nonparametric tests and receiver-operating characteristic (ROC) curve analysis. Results We included 25 patients with AQP4+NMOSD and 26 with DS-NMOSD. The median age at disease onset (p = 0.611) and female sex predominance (p = 0.072) were similar in the 2 groups. The most common syndromes at sampling in both AQP4+NMOSD and DS-NMOSD were myelitis (56% vs 38.5%) and optic neuritis (34.6% vs 32%), with no statistical differences (p = 0.716). Median EDSS at sampling was 3.2 (interquartile range [IQR] 2–7.7) in the AQP4+NMOSD group and 4 (IQR [3–6]) in the DS-NMOSD group (p = 0.974). Serum GFAP, tau, and UCH-L1 levels were higher in patients with AQP4+NMOSD compared with those with DS-NMOSD (median 308.3 vs 103.4 pg/mL p = 0.001; median 1.2 vs 0.5 pg/mL, p = 0.001; and median 61.4 vs 35 pg/mL, p = 0.006, respectively). The ROC curve analysis showed that GFAP, tau, and UCH-L1, but not NfL, values were able to discriminate between AQP4+ and DS-NMOSD (area under the curve (AUC) tau: 0.782, p = 0.001, AUC GFAP: 0.762, p = 0.001, AUC UCH-L1: 0.723, p = 0.006). NfL levels were associated with EDSS at nadir only in patients with AQP4+NMOSD. Discussion Serum GFAP, tau, and UCH-L1 levels discriminate between AQP4+NMOSD and DS-NMOSD. The different biomarker profile of AQP4+NMOSD vs DS-NMOSD suggests heterogeneity of diseases within the latter category and provides useful data to improve our understanding of this disease., H. Zéphir has no disclosure related to this work. Unrelated to this work, H. Zéphir received consulting fees from Alexion, Horizon Therapeutics, Roche, Merck, Biogen Idec, Sanofi, and Novartis. Georgina Arrambide has received speaking honoraria and compensation for consulting services or participation in advisory boards from Merck, Roche, and Horizon Therapeutics; travel support for scientific meetings from Novartis, Roche, and ECTRIMS; is the editor for Europe of the Multiple Sclerosis Journal - Experimental, Translational and Clinical; and is a member of the International Women in Multiple Sclerosis (iWiMS) Network executive committee and of the European Biomarkers in MS (BioMS-eu) Consortium steering committee; J. Villacieros-Álvarez has received a grant from Instituto de Salud Carlos III, Spain, FI21/00282; A. Cobo-Calvo has received a grant from Instituto de Salud Carlos III, Spain, JR19/00007; E.P. Flanagan has served on advisory boards for Alexion, Genentech, Horizon Therapeutics, and UCB. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr. Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr. Flanagan has received funding from the NIH (R01NS113828). Dr. Flanagan is a member of the medical advisory board of the MOG project. Dr. Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. S. Mariotto received speaker honoraria from Novartis, Biogen, and Sanofi. Go to Neurology.org/NN for full disclosures.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

  • Lunemann, Jan
  • Valls Carbó, Adrián
  • Fernández, Victoria
  • Villacieros-Álvarez, Javier
  • Sepulveda, Maria
  • Dinoto, Alessandro
  • Vilaseca Jolonch, Andreu
  • Castillo Juárez, Mireia
  • Espejo, Carmen
  • Cobo-Calvo, Alvaro
  • Tintore, Mar
  • Comabella Lopez, Manuel
  • Arrambide, Georgina
  • Montalban, Xavier
  • Bollo, Luca
Complement activation; Clinical outcomes; Myelin oligodendrocyte glycoprotein, Perfiles de activación; Resultados clínicos; Glucoproteína de oligodendrocito de mielina, Activació del complement; Resultats clínics; Glicoproteïna d'oligodendròcits de mielina, Background and Objectives The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis are lacking. We aimed to investigate the value of complement factors (CFs) as diagnostic and prognostic biomarkers in patients with MOGAD. Methods Multicentric retrospective cohort study including patients with MOGAD, multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD) with available paired serum and CSF samples. A panel of CFs were measured by multiplex ELISA, and the levels were compared between the 3 conditions. Univariable and multivariable analyses were performed to evaluate the association between levels of CFs and relapse and disability outcomes in MOGAD patients. Results Ninety-four patients (MOGAD, n = 60; MS, n = 18; AQP4-NMOSD, n = 16) were included. Mean (SD) age at sampling was 39.4 (16.7), 40.7 (7.0), and 43.3 (21.0), respectively. Female were predominant, especially in AQP4-NMOSD (88%). Combination of the serum levels of C3a, C4a, and C3a/C3 ratio showed excellent potential to discriminate MOGAD from patients with MS (area under the curve [AUC] [95% CI] 0.95 [0.90–0.99]) and from AQP4-NMOSD (AUC 0.88 [0.76–1.00]). In patients with MOGAD, CSF levels of CFs of the classical/lectin pathway influenced relapse-related outcomes, and lower C4 levels were associated with higher number of relapses during follow-up (incidence rate ratio [95% CI] 0.88 [0.78–0.99]; p = 0.04 in multivariable analysis), and a high C4a/C4 ratio was associated with increased risk of second relapse during the first year (hazard ratio [95% CI] 3.68 [1.26–10.78]; p = 0.02 in multivariable analysis). Time to second relapse was shorter in patients with MOGAD with a high CSF C4a/C4 ratio (log-rank p = 0.01). CSF levels of the membrane attack complex SC5b9 influenced disability-related outcomes, and baseline CSF SC5b9 levels were higher in patients who reached the final Expanded Disability Status Scale (EDSS) ≥ 3.0 (p = 0.002), and elevated SC5b9 levels were associated with increased risk of reaching EDSS ≥ 3.0 (odds ratio [95% CI] 1.79 [1.16–3.67]; p = 0.04 in multivariable analyses). Discussion Our results suggest that serum and CSF levels of CFs have diagnostic and prognostic value respectively in patients with MOGAD. These findings support the use of complement inhibitors as a therapeutic approach in these patients., The study was funded thanks to a legacy from Mrs. Adela Arbó. J.V.-A. received grant from Instituto de Salud Carlos III, Spain; FI21/00282.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease

  • Mulero, Patricia
  • Rubio-Flores, Laura
  • Villacieros-Álvarez, Javier
  • Espejo, Carmen
  • Dinoto, Alessandro
  • Rovira, Alex
  • Auger, Cristina
  • Tintore, Mar
  • Cobo-Calvo, Alvaro
  • Arrambide, Georgina
  • Montalban, Xavier
Serum Cytokines; Prognosis; Myelin oligodendrocyte glycoprotein, Citocinas séricas; Pronóstico; Glicoproteína de oligodendrocitos de mielina, Citocines sèriques; Pronòstic; Glicoproteïna d'oligodendròcits de mielina, Objectives To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (≤3 months from disease onset) and follow-up (≥6 months from the baseline), and age-matched and time to sampling–matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Results Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non–optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). Discussion This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions., This study has been funded by Instituto Carlos III through the projects PI20/00800 granted to A.C.-C. and Fondation pour l'aide à la recherche sur la sclérose en plaques (ARSEP) (ARSEP-1276). A. Cobo-Calvo is supported by Joan Rodes contract JR19/00007 and Javier Villacieros-Álvarez by P-FIS grant FI21/00282.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder

  • Carta, Sara
  • Dinoto, Alessandro
  • Capobianco, Marco
  • Valentino, Paola
  • Montarolo, Francesca
  • Sala, Arianna
  • Villacieros-Álvarez, Javier
  • Cobo-Calvo, Alvaro
  • Arrambide, Georgina
Serum biomarker; Neuromyelitis optica spectrum disorder, Biomarcadores séricos; Trastorno del espectro de neuromielitis óptica, Biomarcadors sèrics; Trastorn de l'espectre de neuromielitis òptica, Background and Objectives Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) serum levels are useful to define disease activity in different neurologic conditions. These biomarkers are increased in patients with aquaporin-4 antibody–positive NMOSD (AQP4+NMOSD) during clinical attacks suggesting a concomitant axonal and glial damage. However, there are contradictory results in double seronegative NMOSD (DS-NMOSD). The aim of this study was to characterize the neuronal, axonal, and glial damage of DS-NMOSD in comparison with AQP4+NMOSD. Methods Patients with DS-NMOSD (i.e., for AQP4 and myelin oligodendrocyte glycoprotein antibodies—MOG-Abs) and age-matched AQP4+NMOSD diagnosed according to the latest diagnostic criteria and with available serum samples obtained within 3 months from onset/relapse were retrospectively enrolled from 14 international centers. Clinical and radiologic data were collected. Serum NfL, GFAP, tau, and UCH-L1 levels were determined using an ultrasensitive paramagnetic bead–based ELISA (SIMOA). Statistical analysis was performed using nonparametric tests and receiver-operating characteristic (ROC) curve analysis. Results We included 25 patients with AQP4+NMOSD and 26 with DS-NMOSD. The median age at disease onset (p = 0.611) and female sex predominance (p = 0.072) were similar in the 2 groups. The most common syndromes at sampling in both AQP4+NMOSD and DS-NMOSD were myelitis (56% vs 38.5%) and optic neuritis (34.6% vs 32%), with no statistical differences (p = 0.716). Median EDSS at sampling was 3.2 (interquartile range [IQR] 2–7.7) in the AQP4+NMOSD group and 4 (IQR [3–6]) in the DS-NMOSD group (p = 0.974). Serum GFAP, tau, and UCH-L1 levels were higher in patients with AQP4+NMOSD compared with those with DS-NMOSD (median 308.3 vs 103.4 pg/mL p = 0.001; median 1.2 vs 0.5 pg/mL, p = 0.001; and median 61.4 vs 35 pg/mL, p = 0.006, respectively). The ROC curve analysis showed that GFAP, tau, and UCH-L1, but not NfL, values were able to discriminate between AQP4+ and DS-NMOSD (area under the curve (AUC) tau: 0.782, p = 0.001, AUC GFAP: 0.762, p = 0.001, AUC UCH-L1: 0.723, p = 0.006). NfL levels were associated with EDSS at nadir only in patients with AQP4+NMOSD. Discussion Serum GFAP, tau, and UCH-L1 levels discriminate between AQP4+NMOSD and DS-NMOSD. The different biomarker profile of AQP4+NMOSD vs DS-NMOSD suggests heterogeneity of diseases within the latter category and provides useful data to improve our understanding of this disease., H. Zéphir has no disclosure related to this work. Unrelated to this work, H. Zéphir received consulting fees from Alexion, Horizon Therapeutics, Roche, Merck, Biogen Idec, Sanofi, and Novartis. Georgina Arrambide has received speaking honoraria and compensation for consulting services or participation in advisory boards from Merck, Roche, and Horizon Therapeutics; travel support for scientific meetings from Novartis, Roche, and ECTRIMS; is the editor for Europe of the Multiple Sclerosis Journal - Experimental, Translational and Clinical; and is a member of the International Women in Multiple Sclerosis (iWiMS) Network executive committee and of the European Biomarkers in MS (BioMS-eu) Consortium steering committee; J. Villacieros-Álvarez has received a grant from Instituto de Salud Carlos III, Spain, FI21/00282; A. Cobo-Calvo has received a grant from Instituto de Salud Carlos III, Spain, JR19/00007; E.P. Flanagan has served on advisory boards for Alexion, Genentech, Horizon Therapeutics, and UCB. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr. Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr. Flanagan has received funding from the NIH (R01NS113828). Dr. Flanagan is a member of the medical advisory board of the MOG project. Dr. Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. S. Mariotto received speaker honoraria from Novartis, Biogen, and Sanofi. Go to Neurology.org/NN for full disclosures.